NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 218 filers reported holding NEVRO CORP in Q3 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $3,616,000 | +0.3% | 49,990 | +12.5% | 0.00% | 0.0% |
| Q4 2021 | $3,604,000 | -18.1% | 44,451 | +17.6% | 0.00% | 0.0% |
| Q3 2021 | $4,398,000 | -20.6% | 37,787 | +13.2% | 0.00% | -33.3% |
| Q2 2021 | $5,536,000 | +20.1% | 33,390 | +1.0% | 0.00% | 0.0% |
| Q1 2021 | $4,611,000 | -23.1% | 33,053 | -4.6% | 0.00% | -25.0% |
| Q4 2020 | $5,996,000 | +9.6% | 34,641 | -11.8% | 0.00% | 0.0% |
| Q3 2020 | $5,471,000 | +16.2% | 39,274 | -0.4% | 0.00% | 0.0% |
| Q2 2020 | $4,709,000 | +3.7% | 39,419 | -13.2% | 0.00% | 0.0% |
| Q1 2020 | $4,539,000 | +15.3% | 45,397 | +35.5% | 0.00% | +33.3% |
| Q4 2019 | $3,937,000 | +124.7% | 33,492 | +64.4% | 0.00% | +200.0% |
| Q3 2019 | $1,752,000 | +38.2% | 20,374 | +4.2% | 0.00% | 0.0% |
| Q2 2019 | $1,268,000 | -33.7% | 19,561 | -36.1% | 0.00% | -50.0% |
| Q1 2019 | $1,912,000 | +63.1% | 30,595 | +1.5% | 0.00% | +100.0% |
| Q4 2018 | $1,172,000 | -31.6% | 30,132 | +0.2% | 0.00% | 0.0% |
| Q3 2018 | $1,713,000 | -29.1% | 30,060 | -0.7% | 0.00% | -50.0% |
| Q2 2018 | $2,417,000 | +10.2% | 30,265 | +19.6% | 0.00% | 0.0% |
| Q1 2018 | $2,194,000 | +18.7% | 25,309 | -5.5% | 0.00% | 0.0% |
| Q4 2017 | $1,849,000 | -57.4% | 26,781 | -43.9% | 0.00% | -60.0% |
| Q3 2017 | $4,342,000 | +27.4% | 47,774 | +4.3% | 0.01% | +25.0% |
| Q2 2017 | $3,409,000 | -37.0% | 45,806 | -20.7% | 0.00% | -50.0% |
| Q1 2017 | $5,409,000 | +94.5% | 57,729 | +50.8% | 0.01% | +100.0% |
| Q4 2016 | $2,781,000 | -50.0% | 38,276 | -28.2% | 0.00% | -50.0% |
| Q3 2016 | $5,565,000 | +35.9% | 53,306 | -4.0% | 0.01% | +33.3% |
| Q2 2016 | $4,096,000 | +2.0% | 55,529 | -22.2% | 0.01% | 0.0% |
| Q1 2016 | $4,015,000 | +183.3% | 71,373 | +240.0% | 0.01% | +200.0% |
| Q4 2015 | $1,417,000 | +240.6% | 20,991 | +46.0% | 0.00% | +100.0% |
| Q3 2015 | $416,000 | -5.2% | 14,374 | +76.1% | 0.00% | 0.0% |
| Q2 2015 | $439,000 | +13.1% | 8,162 | +0.8% | 0.00% | 0.0% |
| Q1 2015 | $388,000 | +24.0% | 8,101 | +0.1% | 0.00% | 0.0% |
| Q4 2014 | $313,000 | – | 8,092 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |